1IXD

Solution structure of the CAP-GLY domain from human cylindromatosis tomour-suppressor CYLD


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma

Saito, K.Kigawa, T.Koshiba, S.Sato, K.Matsuo, Y.Sakamoto, A.Takagi, T.Shirouzu, M.Yabuki, T.Nunokawa, E.Seki, E.Matsuda, T.Aoki, M.Miyata, Y.Hirakawa, N.Inoue, M.Terada, T.Nagase, T.Kikuno, R.Nakayama, M.Ohara, O.Tanaka, A.Yokoyama, S.

(2004) Structure 12: 1719-1728

  • DOI: 10.1016/j.str.2004.07.012
  • Primary Citation of Related Structures:  
    1IXD

  • PubMed Abstract: 
  • CYLD was originally identified as the human familial cylindromatosis tumor suppressor. Recently, it was reported that CYLD directly interacts with NEMO/IKKgamma and TRAF2 in the NF-kappaB signaling pathway. The two proteins bind to a region of CYLD t ...

    CYLD was originally identified as the human familial cylindromatosis tumor suppressor. Recently, it was reported that CYLD directly interacts with NEMO/IKKgamma and TRAF2 in the NF-kappaB signaling pathway. The two proteins bind to a region of CYLD that contains a Cys-box motif and the third cytoskeleton-associated protein-glycine conserved (CAP-Gly) domain. Here we report that the third CAP-Gly domain of CYLD specifically interacts with one of the two proline-rich sequences of NEMO/IKKgamma. The tertiary structure of the CAP-Gly domain shares the five-stranded beta sheet topology with the SH3 domain, which is well known as a proline-rich sequence-recognition domain. However, chemical shift mapping revealed that the peptide binding site of the CAP-Gly domain is formed without the long peptide binding loop characteristic of the SH3 domain. Therefore, CAP-Gly is likely to be a novel proline-rich sequence binding domain with a mechanism different from that of the SH3 domain.


    Organizational Affiliation

    RIKEN Genomic Sciences Center, 1-7-22 Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Cylindromatosis tumour-suppressor CYLDA104Homo sapiensMutation(s): 0 
Gene Names: fh04363CYLDCYLD1KIAA0849HSPC057
EC: 3.1.2.15 (PDB Primary Data), 3.4.19.12 (UniProt)
Find proteins for Q9NQC7 (Homo sapiens)
Explore Q9NQC7 
Go to UniProtKB:  Q9NQC7
NIH Common Fund Data Resources
PHAROS  Q9NQC7
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 
  • OLDERADO: 1IXD Olderado

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2002-12-19
    Type: Initial release
  • Version 1.1: 2008-04-27
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance